1. Purpose

The purpose of this guideline is to optimise the use of antibiotic prophylaxis for surgical procedures at the Women’s in Parkville and in Sandringham.

Surgical site infections (SSIs) are a common adverse event in hospitalised patients: 8-10% of gynaecological surgery patients undergoing an operative procedure will develop an SSI. SSIs have been shown to increase mortality, readmission rate and length of hospital stay. Appropriate and timely antibiotic prophylaxis has been shown to be highly effective in reducing the incidence of SSI. The need for surgical antibiotic prophylaxis varies according to the type of procedure and its associated risk of SSI.

A number of studies across a range of surgical procedures have shown that there is a narrow window of opportunity for the administration of effective antimicrobial prophylaxis. Antibiotics need to be present in the tissue at the time of incision in order to be effective. Ideally prophylactic antibiotics should cover the narrowest spectrum of organisms possible in order to minimise the development of bacterial resistance. For this reason it is important to consider the likely source of pathogens in each type of surgery. For most infections that occur after obstetric or gynaecological surgery, the source of pathogens is the endogenous flora of the patient’s vagina or skin. The endogenous flora of the genital tract is polymicrobial, consisting of anaerobes, Gram negative aerobes and Gram positive cocci. In contrast, laparoscopic procedures that do not breach any mucosal surfaces are more commonly contaminated with skin organisms only (usually Gram positive organisms such as Staphylococci).

2. Definitions

Surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place.

Antibiotic prophylaxis is the use of antibiotics before, during, or after a diagnostic, therapeutic, or surgical procedure to prevent infectious complications. For surgical prophylaxis, these can generally be given prior to surgical incision.

3. Responsibilities

Surgeons are responsible for requesting the timely administration of appropriate antibiotic prophylaxis for their surgical patients.

Anaesthetists are responsible for liaison with surgeons and the provision of appropriate and timely antibiotic prophylaxis.

Pharmacists are responsible for ensuring prompt availability of required antibiotics. They are also responsible for provision of information to medical and nursing staff regarding doses of antibiotics and administration.

4. Guideline

Table 1 outlines recommended timing and choice of prophylactic antibiotics for surgical procedures at the Women’s.

An alternative choice of antibiotic is provided where appropriate (e.g. for a patient with penicillin allergy).

The National Health and Medical Research Council (NHMRC) level of evidence for each recommendation is included in the Table. For some procedures, such as Caesarean section and hysterectomy, antibiotic prophylaxis is clearly indicated. For other procedures, such as insertion of an intra-uterine device, medical termination of pregnancy and diagnostic laparoscopy, antibiotic prophylaxis is usually not required. For other procedures, the evidence is less clear and recommendations are based upon expert agreement until further research evidence becomes available.
Table 1: Antibiotics for surgical prophylaxis
Patients with immediate hypersensitivity reactions (eg. urticaria, angio-oedema, bronchospasm, anaphylaxis) to penicillins, avoid use of penicillins and cephalosporins.

Patients allergic to penicillins (excluding immediate hypersensitivity reactions eg. urticaria, angio-oedema, bronchospasm and anaphylaxis), use of cephalosporins can be considered.

<table>
<thead>
<tr>
<th>Surgery</th>
<th>1st line</th>
<th>Level of evidence</th>
<th>Alternative</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Obstetric</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Caesarean section<sup>10-13</sup>    | Cefazolin (cephazolin) 2 g IV, within 60 minutes (ideally 15-30 minutes) before skin incision. | I                 | Clindamycin 600 mg IV over at least 20 minutes, within 60 minutes (ideally 15-30 minutes) before surgical incision  
<sup>or</sup> Vancomycin 25 mg/kg IV (maximum 2g) | Antibiotics prior to skin incision reduce maternal infection rate in emergency caesarean section. |
| Termination of pregnancy (surgical)<sup>13-16</sup> | Screen patient for STIs: C. trachomatis, N. gonorrhoeae, M. genitalium and bacterial vaginosisis. Treat the woman and her partner(s) prior to ToP<sup>17</sup>. | Consensus         | If STI screening <sup>not</sup> performed or results unavailable:  
Azithromycin 1 g oral stat |                                                                         |
| Termination of pregnancy (medical)<sup>13</sup> | Not indicated                                                          | I                 |                                                      |                                                                         |
| Manual removal of placenta<sup>18-19</sup> | Cefazolin (cephazolin) 2 g IV, at the time of induction  
+ Metronidazole 500 mg IV, ending the infusion at the time of induction | III-3              | Clindamycin 600 mg IV  
+ Gentamicin 2 mg/kg IV (maximum 560 mg) |                                                                         |
| 3<sup>rd</sup> and 4<sup>th</sup> degree vaginal tears<sup>13,20-24</sup> | Cefazolin (cephazolin) 2 g IV within 60 minutes (ideally 15-30 minutes) before the repair  
+ Metronidazole 500 mg IV within 60 minutes (ideally 15-30 minutes) before the repair  
Followed by trimethoprim/sulfamethoxazole 160/800 orally BD | Consensus           | Clindamycin 600 mg IV  
+ Gentamicin 2 mg/kg IV (maximum 560 mg) within 60 minutes (ideally 15-30 minutes) before the repair  
Followed by trimethoprim/sulfamethoxazole 160/800 orally BD |                                                                         |
### Surgical Antibiotic Prophylaxis Guideline

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Prophylaxis Details</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gynaecological</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Note:</strong> Prophylactic antibiotics for vaginal packs can be administered for the duration of vaginal pack use which is usually 24-48 hours.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hysterectomy (vaginal)</td>
<td>Cefazolin (cephazolin) 2 g IV, within 60 minutes (ideally 15-30 minutes) before surgical incision (repeat dose if procedure &gt; 3 hours) + Metronidazole 500 mg IV, within 60 minutes (ideally 15-30 minutes) before surgical incision</td>
<td>Clindamycin 600 mg IV + Gentamicin 2 mg/kg IV (maximum 560 mg)</td>
</tr>
<tr>
<td>Hysterectomy (abdominal)</td>
<td>Cefazolin (cephazolin) 2 g IV, within 60 minutes (ideally 15-30 minutes) before surgical incision (repeat dose if procedure &gt; 3 hours)</td>
<td>Clindamycin 600 mg IV over at least 20 minutes, within 60 minutes (ideally 15-30 minutes) before surgical incision or Vancomycin 25 mg/kg IV (maximum 2 g)</td>
</tr>
<tr>
<td>Urogynaecological procedures</td>
<td>Cefazolin (cephazolin) 2 g IV, within 60 minutes (ideally 15-30 minutes) before surgical incision (repeat dose if procedure &gt; 3 hours)</td>
<td>Clindamycin 600 mg IV + Gentamicin 2 mg/kg IV (maximum 560 mg)</td>
</tr>
<tr>
<td>Procedure</td>
<td>Prophylaxis</td>
<td>Guidelines</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Hysterosalpingography or Hysteroscopy or Chromotubation for patients with dilated tubes or a history of PID or tubal damage(^{28})</td>
<td><strong>+</strong> Metronidazole 500 mg IV, within 60 minutes (ideally 15-30 minutes) before surgical incision <strong>Azithromycin 1 g oral stat</strong></td>
<td>Consensus</td>
</tr>
<tr>
<td>Hysterosalpingography or Hysteroscopy or Chromotubation with NO history of PID and normal tubes on visualisation(^{29})</td>
<td><strong>Not indicated</strong></td>
<td>IV</td>
</tr>
<tr>
<td>IUD insertion(^{30})</td>
<td><strong>Not indicated</strong></td>
<td>I</td>
</tr>
<tr>
<td>Endometrial biopsy(^{31})</td>
<td><strong>Not indicated</strong></td>
<td>IV</td>
</tr>
<tr>
<td>Laparoscopy(^{32}) (diagnostic or laparoscopy without breaching bowel/uterine/vaginal cavity)</td>
<td><strong>Not indicated</strong></td>
<td>II</td>
</tr>
<tr>
<td>Laparoscopy (breach of bowel/uterine/vaginal cavity or conversion to operative laparotomy)</td>
<td><strong>Cefazolin (cephazolin) 2 g IV, within 60 minutes (ideally 15-30 minutes) before surgical incision (repeat dose if procedure &gt; 3 hours)</strong>  <strong>+</strong> Metronidazole 500 mg IV, within 60 minutes (ideally 15-</td>
<td>Consensus</td>
</tr>
</tbody>
</table>

**Patients should be screened and treated for STIs prior to insertion:** C. trachomatis, N. gonorrhoeae, M. genitalium and bacterial vaginosis.
30 minutes) before surgical incision

NHMRC Levels of Evidence:
Level I: A systematic review of level II studies
Level II: A randomised controlled trial
Level III-1: A pseudo-randomised controlled trial
Level III-2: A comparative study with concurrent controls
Level III-3: A comparative study without concurrent controls
Level IV: A case series with either post-test outcomes or pre-test/ post-test outcomes

5. Evaluation, monitoring and reporting of compliance to this guideline
Compliance to this guideline or procedure will be monitored, evaluated and reported through:
1. Review of hysterectomy and caesarean surgical site infection rate
2. Spot audits of practice under the Quality Use of Medicines program
3. Laboratory review of infection clusters and antimicrobial resistance

6. References
9. National Health and Medical Research Council. NHMRC levels of evidence and grades for recommendations for developers of guidelines: National Health and Medical Research Council; 2009.


7. Legislation/Regulations related to this guideline


Please ensure that you adhere to the below disclaimer:

**PGP Disclaimer Statement**

The Royal Women’s Hospital Clinical Guidelines present statements of ‘Best Practice‘ based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women’s this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it.

Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women’s Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated.

In view of the possibility of human error and / or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site.

You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner.

NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines.